Manley Corey J 4
4 · OMNICELL, INC. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Omnicell (OMCL) EVP Corey Manley Receives Award and Sells Shares
What Happened Corey J. Manley, EVP & Chief Legal/Administrative Officer of Omnicell (OMCL), reported the vesting/conversion of 22,445 performance-based restricted stock units (award) on March 15, 2026 (recorded at $0.00). To cover taxes on the vesting, 3,819 shares were withheld (disposed) at $34.40 per share for a tax-withholding value of $131,374. On March 16, 2026 he sold 7,405 shares in an open-market transaction at $34.69 per share, yielding $256,879. Total proceeds/dispositions reported equal approximately $388,253 (withholding + sale).
Key Details
- Transaction types: A (award) — 22,445 RSUs; F (tax withholding) — 3,819 shares withheld at $34.40 ($131,374); S (open-market sale) — 7,405 shares at $34.69 ($256,879).
- Dates: Award & withholding reported 2026-03-15; open-market sale 2026-03-16; filing date 2026-03-17.
- Sale executed under a Rule 10b5-1 trading plan adopted June 13, 2025 (footnote F3). Reported sale price is exact $34.69 for all shares (footnote F4).
- Footnote F1: These were performance-based RSUs originally granted March 15, 2025; on March 5, 2026 the company determined performance criteria were met (100% of target). 25% vested on the one-year anniversary; remaining units vest quarterly over three years (May/Aug/Nov/Feb).
- Footnote F2: Withholding of 3,819 shares was to cover taxes due on vesting (not an independent sale for investment purposes).
- Shares owned after the transactions: Not disclosed in this Form 4.
- Filing timeliness: Report was filed March 17, 2026 for transactions on March 15–16, 2026 (no late filing indicated).
Context This filing reflects vested performance RSUs and routine tax withholding, followed by an open-market sale under a preset 10b5-1 plan. Withholding to cover taxes is a common administrative disposition and does not by itself indicate a change in the insider’s view of the company.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-15+22,445→ 107,941.339 total - Tax Payment
Common Stock
[F2]2026-03-15$34.40/sh−3,819$131,374→ 104,122.339 total - Sale
Common Stock
[F3][F4]2026-03-16$34.69/sh−7,405$256,879→ 96,717.339 total
Footnotes (4)
- [F1]Reflects performance-based restricted stock units that were previously granted on March 15, 2025, subject to the Company meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index. On March 5, 2026 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 22,445 performance-based restricted stock units (100% of target) of which 25% vested upon the one year anniversary of the grant date. The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).
- [F2]Reflects withholding of shares to cover taxes due in connection with the vesting of restricted stock units.
- [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
- [F4]The price reported in Column 4 is an exact price of $34.69 for all shares sold.